DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients

Phase 1

Completed

Conditions: Ovarian Cancer
Endometrial Cancer
Peritoneal Cancer
Cervical Cancer
Fallopian Tube Cancer
Breast Cancer

Interventions: Drug: Docetaxel
Drug: PTK787

First Posted Date: 2005-12-23

Last Posted Date: 2018-07-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 24

Registration Number: NCT00268918

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer

Phase 1

Conditions: Lung Cancer

Interventions: Drug: Near Infrared Imaging

First Posted Date: 2005-12-13

Last Posted Date: 2022-04-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 57

Registration Number: NCT00264602

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 1 locations

Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma

Phase 1

Completed

Conditions: Renal Cell Carcinoma
Melanoma
Sarcoma, Clear Cell
Sarcoma, Alveolar Soft Part

Interventions: Biological: GVAX

First Posted Date: 2005-11-28

Last Posted Date: 2021-03-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 12

Registration Number: NCT00258687

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States

Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: Taxotere
Drug: Cisplatin
Drug: CPT-11

First Posted Date: 2005-11-10

Last Posted Date: 2012-08-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 46

Registration Number: NCT00251407

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia

Phase 1

Completed

Conditions: Acute Lymphocytic Leukemia
Leukemia, Myelocytic, Acute

First Posted Date: 2005-11-10

Last Posted Date: 2011-03-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 52

Registration Number: NCT00251368

Locations: 🇺🇸
Massachusetts General Hosptial, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Gemcitabine
Drug: 5-Fluorouracil
Procedure: Radiation Therapy

First Posted Date: 2005-11-10

Last Posted Date: 2016-12-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 40

Registration Number: NCT00251355

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma

Phase 2

Completed

Conditions: Non-Hodgkin's Lymphoma

First Posted Date: 2005-11-10

Last Posted Date: 2010-01-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00251394

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia

Phase 2

Completed

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: Bortezomib
Drug: Dexamethasone
Drug: Rituximab

First Posted Date: 2005-11-09

Last Posted Date: 2016-04-08

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 23

Registration Number: NCT00250926

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Peritoneal Cancer
Ovarian Cancer

Interventions: Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2005-10-03

Last Posted Date: 2018-08-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 44

Registration Number: NCT00230542

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer
Stomach Cancer

First Posted Date: 2005-09-22

Last Posted Date: 2009-04-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 32

Registration Number: NCT00215462

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy